Ketesse Training Iraq 2024 PDF

STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY Ketesse Training Iraq April, 2024 Rachal Shami  2 tablets 25 gm Dexketoprofen trometamol t...

STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY Ketesse Training Iraq April, 2024 Rachal Shami  2 tablets 25 gm Dexketoprofen trometamol tablets Tablets : pack of 20 tablets granules STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 25 gm Dexketoprofen trometamol Granules KETESSE PORTFOLIO for oral solution Sachets pack of 20 injection 50gm/2ml Dexketoprofen trometamol Solution for injection or infusion Available pack: 5 vials Reconstructed Market 3 Market Definition M01A ANTIRHEUMATIC NON-STEROID Therapeutic area (ATC code) N02B NON-NARCOTIC ANALGESICS KETESSE® Molecules All NSAID molecules excluding paracetamol and STRICTLY CONFIDENTIAL FOR INTERNAL USE Tablets paracetamol +caffeine products Reconstruct Mkt Pharmaceutical forms Solid oral formulations: tablets, capsules KETESSE® ONLY Molecules All segment including NSAIDs, paracetamol and tramadol Injection Pharmaceutical forms Injectable forms : vials, ampoules- all pack sizes KETESSE® Molecules All NSAID molecules Sachet Pharmaceutical forms Solid oral formulations in sachet or granules only  4 STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY Tablets Titolo della presentazione Data e luogo  5 KETESSE TABLET Product Description ▪ Dexketoprofen trometamol 25 mg ▪ Pack of 20 film- coated tablets ▪ Symptomatic treatment of pain of mild to moderate intensity, such as musculo-skeletal pain,dysmenorrhoea, dental pain. STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY Product Features ▪ High potency and efficacy as analgesic providing pain relief. ▪ Fast onset ▪ High safety and tolerability profile Posology ▪ The recommended dose is 25 mg every 8 hours. ▪ The total daily dose should not exceed 75mg.  6 N02B NON NARCOTICS ANALGESICS/M01A1 ANTIRHEUMATICS-NON-S-PLN Defined Market*: N02B NON NARCOTICS ANALGESICS/M01A1 ANTIRHEUMATICS-NON-S-PLN- oral only- Removing plain Paracetamol and Paracetamol + Caffeine Valued at 41M USD with 37M units sold with 1% 5Y CAGR% (units) and -1% value UNITS VA L U E - U S D +1% 36,980,143 35,877,939 35,364,252 43,034,602 43,539,564 -1% 33,920,306 41,501,076 STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 40,200,047 39,893,554 31,950,978 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Source: AMS MAT Q4  7 Competitive Landscape- Molecule Breakdown DICLOFENAC COMBINATION OF (NEFOPAM,PARACETAMOL) MEFENAMIC ACID ETODOLAC MEFENAMIC ACID INDOMETACIN COMBINATION OF (ACECLOFENAC,PARACETAMOL) COMBINATION OF (PARACETAMOL,CODEINE) DICLOFENAC COMBINATION OF (IBUPROFEN,PARACETAMOL,CAFEEINE) MELOXICAM COMBINATION OF (PARACETAMOL,CAFFEINE,C IBUPROFEN ACECLOFENAC COMBINATION OF (IBUPROFEN,PARACETAMOL,CAFEEINE) COMBINATION OF (DICLOFENAC,HYDROXOCOB COMBINATION OF (ACECLOFENAC,PARACETAMOL) PIROXICAM NAPROXEN DEXKETOPROFEN TROMETAMOL MELOXICAM COMBINATION OF (DICLOFENAC,PARACETAMOL,CAFFEINE) IBUPROFEN OTHERS NAPROXEN DEXKETOPROFEN TROMETAMOL ACECLOFENAC COMBINATION OF (PARACETAMOL,CAFFEINE,CODEINE,) OTHERS VA L U E - U S D UNITS +1% STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY +8% 41,043,700 41,950,591 36,980,143 40,408,633 35,364,252 2,879,183 (8%) 5,924,978 5,837,028 8,151,396 2,705,787 31,950,978 2,362,897 2,945,630 2,493,026 (14%) (14%) (19%) (6%) (7%) (8%) (7%) 1,886,853 2,412,722 2,284,510 2,829,417 16,594,004 872,308 8,005,165 (5%) 6,756,767 (6%) 14,920,818 6,886,594 (7%) (8%) (45%) (2%) (20%) 2,090,982 (17%) 2,460,001 2,210,730 (42%) (16%) 14,399,103 694,884 937,728 755,171 (5%) (6%) (5%) (45%) (2%) (3%) (2%) 3,369,821 2,125,693 3,737,235 1,536,173 1,550,244 695,140 621,556 736,687 (5%) (9%) (4%) 4,854,044 (4%) (8%) (2%) (2%) (2%) 1,142,209 4,780,755 1,062,788 (12%) 1,224,185 4,119,224 4,644,491 4,694,109 552,603 604,273 718,940 (11%) (3%) (12%) (3%) 3,794,524 (3%) 3,621,759 (12%) (13%) (9%) (2%) (2%) (2%) 679,014 2,680,588 943,965 1,078,808 (11%) 580,178 4,066,205 810,752 3,909,521 500,496 (2%) (7%) (2%) (3%) 3,421,750 (2%) (11%) (2%) (11%) (1%) 774,358 752,998 595,681 (11%) (2%) 2,794,304 (2%) (1%) 598,095 582,675 367,349 2,224,611 299,949 (7%) 481,892 463,105 (2%) (2%) (1%) (5%) 375,444 302,669 292,620 (1%) (1%) (1%) (1%) (1%) (1%) 843,653 515,078 449,515 39,430 23,761 25,000 6,593,557 (2%) (1%) (1%) 2,325,186 2,599,545 2,191,348 5,863,006 5,339,211 (0%) (0%) (0%) (16%) 388,749 206,055 234,047 (7%) (7%) (6%) (15%) (13%) (1%) (1%) (1%) 2020 2021 2022 2020 2021 2022 Source: AMS MAT Q4  8 Competitive Landscape- Brands More than 600 brands exist in the Iraqi market MEFRIL OPTIFENAC DIVON-SR FENDOL PONSTAN FORTE OLFEN DOLOGAN DENK NO PAIN-VITANE ETOTAC PIOSTAN PIOSTAN LADY APIFEN LOXIM INDOFLAM RAPIDUS OTHERS ACTINAC-PLUS MOBIC MOVENER LOFLAM FENDOL DIVON-SR ACTINAC-PLUS OLFEN ALGESIC DOLOGAN DENK MEFRIL PONSTAN FORTE RAPIDUS NEFEPAN NAPRON 2,126,451 OTHERS MEFLAM PIOSTAN PIOSTAN LADY MOVENER +4% (5%) 2,574,458 1,617,407 (6%) (4%) UNITS V1,524,990 ALUE -USD 1,114,440 (4%) (3%) +5% 1,279,380 1,581,552 1,093,418 (3%) (4%) (3%) STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 1,304,577 1,123,413 1,477,112 1,018,050 36,980,143 41,501,076 35,364,252 (4%) (3%) 39,893,554 (4%) (2%) 663,393 938,731 925,445 4,927,679 922,289 (2%) (3%) (2%) (12%) (2%) 8,652,517 10,999,593 3,555,737 1,011,895 905,454 849,844 4,395,988 919,063 (24%) (30%) (9%) (3%) (2%) (2%) (11%) (2%) 847,680 683,699 1,691,269 747,023 882,084 2,947,298 (2%) 3,064,783 (2%) (4%) (2%) (2%) (8%) 529,479 602,361 548,155 865,276 2,778,487 (8%) (1%) 2,583,660 (2%) (1%) (2%) (8%) 1,052,659 2,452,496 471,656 (7%) 2,537,288 484,487 (3%) 530,888 833,195 1,415,322 (7%) (1%) (1%) (1%) (2%) 1,480,295 (7%) (4%) 812,187 469,149 768,480 686,310 (2%) (4%) (1%) (2%) (2%) 466,604 413,157 619,183 619,761 (1%) (1%) (2%) (1%) 554,521 362,505 405,180 19,717,938 506,830 599,203 (2%) (1%) (1%) (1%) 17,876,039 (1%) (49%) (43%) 418,131 387,412 797,033 516,093 9,305,794 8,244,006 (1%) (1%) (2%) (1%) (26%) (22%) 369,710 378,095 424,958 488,331 (1%) (1%) (1%) (1%) 2021 2022 2021 2022 Source: AMS MAT Q4  9 Dexketoprofen In Iraq 3 brands exist in the market – only 1 consistent- Dexday (Turkish brand composed of dispersible tablet- 50mg) UNITS DEXKETOPROFEN TROMETAMOL 72,505 DEXKETOPROFEN -21% DEXKETOPROFEN + PARACETAMOL 39,430 28,120 19,635 23,761 25,000 STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 17,930 1,705 3,120 2018 2019 2020 2021 2022 VA L U E - U S D 732,654 -23% 388,749 261,168 183,936 206,055 234,047 176,776 7,160 27,121 2018 2019 2020 2021 2022 Source: AMS MAT Q4  10 Dexketoprofen Brands In Iraq DEXKETOPROFEN DEXKETOPROFEN DEXKETOPROFEN + T R O M E TA M O L PA R A C E TA M O L STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 25mg tablet Berlin Chemie 50mg effervescent tablet 25mg tablet + 500mg paracetamol Launched in Q4 2018 Neutec- Turkey Berko Ilac - Turkey Not available anymore Pack od 20:Launched in Q1 2015 Launched in Q4 2022 Av. Price: 9.53 USD Av Price: 8.69 USD Pack of 30: launched in Q2 2021 Av. Price:9.37 USD Source: AMS MAT Q4  11 STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY Granules Titolo della presentazione Data e luogo  KETESSE Granules Product Description ▪ Dexketoprofen trometamol 25 mg ▪ Granules for oral solution ▪ Pack of 20 sachets ▪ Symptomatic treatment of pain of mild to moderate intensity, such as musculo-skeletal pain, dysmenorrhoea, dental pain. STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY Product Features ▪ Lemon flavored granules ▪ Rapidly absorbed ▪ Peak concentration 30% higher compared to tablets Posology ▪ The recommended dose is 25 mg every 8 hours. ▪ The total daily dose should not exceed 75mg. ▪ Dissolve the whole contents of each sachet in a glass of water; shake well to help to dissolve. ▪ The obtained solution should be immediately ingested after reconstitution. 12  13 N02B NON NARCOTICS ANALGESICS/M01A1 ANTIRHEUMATICS-NON-S-PLN Defined Market*: N02B NON NARCOTICS ANALGESICS/M01A1 ANTIRHEUMATICS-NON-S-PLN- granules and sachets only (minus paracetamol) Valued at 4M USD with 0.7M units sold with 1% 5Y CAGR% (units) and 7% value UNITS VA L U E - U S D +7% 5,283,484 +1% 5,099,597 853,122 808,347 STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 4,343,711 711,661 4,063,806 690,769 671,645 3,358,464 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Source: AMS MAT Q4  14 Competitive Landscape- Brands Around 26 brands exist in the Iraqi market as either sachet or granules No dexketoprofen Diclosan and Lofnac both launched Q4 2021- 1% MS in Y1 ASPEGIC DOLFLAM SOLKET DICLOLAB DICLOSAN-SHIBA ASPEGIC OFLAM VIGAFEN K-FLAM LOFNAC VOLTFAST DICLOFAST K-FLAM VIGAFEN REXOPAIN VOLTFAST DICLOFAST HOT LEMON DICLOLAB ASPEGIC-MOROCCO@ OFLAM HOT LEMON DECLOPHEN FAST LOFNAC OTHERS DOLFLAM SOLKET DICLOSAN-SHIBA REXOPAIN OTHERS UNITS VA L U E - U S D +17% 4,098,713 +11% 644,509 STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 3,501,884 1,252,565 580,550 166,440 (31%) (26%) 160,471 802 19,760 1,166,802 133,971 (28%) (0%) (3%) (33%) (3%) 15,979 16,220 111,945 120,273 (3%) 150,380 (3%) (3%) (3%) (23%) 1,250,433 6,904 13,580 2,895 (31%) 62,129 191,693 (1%) (2%) (0%) (2%) (33%) 10,385 11,520 1,151,340 2,421 57,657 94,021 (33%) (2%) (15%) (2%) (0%) (1%) 331,761 3,851 10,820 23,112 51,621 44,020 (8%) 71,010 (1%) (2%) (1%) 232,729 (1%) (7%) 33,728 257,926 (12%) 1,272 10,460 16,070 (6%) 198,130 50,717 34,915 29,160 (5%) (7%) 163,105 (0%) (0%) (2%) 196,901 (5%) (1%) 29,492 (6%) (5%) 180,419 (5%) 340 8,520 4,573 (5%) 38,895 (5%) (5%) (0%) (1%) 290,959 (0%) (1%) 25,298 5,100 7,060 94,946 18,409 23,038 (4%) 28,820 35,372 (8%) 102,522 (1%) (1%) (3%) (0%) (4%) (4%) (1%) (3%) 2021 2022 2021 2022 Source: AMS MAT Q4  15 STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY Injection Titolo della presentazione Data e luogo  16 KETESSE INJECTION Product Description ▪ Dexketoprofen 50 mg/2ml ▪ Pack of 1,5 and 20 vials (most countries have 5) ▪ Injectable solution (2ml) ▪ IV(Bolus+ Infusion) + IM STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY Product Features ▪ High potency and efficacy as analgesic providing pain relief. ▪ Flexible administration ▪ Compatible when given with other molecules ▪ High safety and tolerability profile Posology ▪ The recommended dose is 50 mg every 8 – 12 hours. ▪ If necessary, the administration can be repeated 6 hours apart. ▪ The total daily dose should not exceed 150 mg.  17 N02B NON NARCOTICS ANALGESICS/M01A1 ANTIRHEUMATICS-NON-S-PLN Defined Market*: N02B NON NARCOTICS ANALGESICS/M01A1 ANTIRHEUMATICS-NON-S-PLN- injectables (excluding paracetamol) Valued at 12.M USD with 14M vials sold with -18% 5Y CAGR% (units) and -10% value UNITS* VA L U E - U S D 31,266,515 -10% STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 20,395,272 19,426,521 19,065,124 -18% 20,475,851 15,135,754 18,924,739 12,405,409 15,378,601 14,039,456 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Source: AMS MAT Q4 * Equivalent vials  18 Competitive Landscape- Brands Almost 300 brands – 200 active OLFEN NEFOPAM-VITAPURE DICLOKAN-KANGBAO VOLTEX PLUS OLFEN FLEXO -TURKEY@ KETRO ZAFIN FORTE ALMIRAL DIKLORON PIROX DICLOLAB ISOFENAL DIFEN B12 PANCLO B12 DIOXAFLEX B12 NEPAM OTHERS VOLTEX ALMIRAL KETRO OTHERS ACUPAN NEFOPAM-VITAPURE ISOFENAL DIKLORON DIFEN B12 REACTINE PANCLO B12 PIROCOMPLEX NEFOPAM MEDISOL HAYAMOL PLUS INDOLOR HAYAMOL PLUS ACUPAN ZELOXIM 601,050 (4%) UNITS* 423,440 VA L U E - U S D (3%) 601,987 409,200 (5%) (3%) 559,315 STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY -9% 398,600 15,135,754 (5%) 15,378,601 -18% (3%) 1,137,291 509,337 1,586,137 451,930 365,370 14,039,456 (8%) (4%) (10%) (3%) (3%) 838,584 984,255 400,199 555,490 364,820 (6%) (6%) 3,030,410 12,405,419 (3%) 647,730 (4%) (3%) 1,903,323 (22%) 300,528 666,745 (4%) 518,728 363,300 (13%) 550,295 2,351,765 (2%) (4%) (3%) (4%) 1,079,141 (3%) 370,983 221,971 (19%) 267,064 35,380 338,000 752,820 609,411 (8%) 644,637 (2%) 905,043 (2%) (0%) (2%) (1%) 916,880 (5%) (4%) (4%) (7%) 257,463 228,040 322,200 753,550 (2%) (6%) 333,276 (1%) (2%) 2,777,985 606,691 (6%) 361,090 (2%) 250,447 328,440 298,380 (18%) (5%) 346,842 (2%) 376,973 (2%) (2%) (2%) (2%) 456,289 (2%) 205,073 206,934 293,760 338,736 (3%) 11,335 (2%) (1%) (2%) (2%) (0%) 204,239 225,696 276,000 218,745 (2%) 6,535,409 (1%) (2%) (1%) 196,051 (42%) 30,055 275,957 4,351,281 330,528 (2%) (0%) (2%) 4,624,804 (31%) (2%) 3,684,740 177,220 239,136 (31%) (1%) (2%) (30%) 174,708 2021 2022 (1%) 2021 2022 Source: AMS MAT Q4 * Equivalent vials  19 Dexketoprofen In Iraq 2 brands existed- no sales after 2020 UNITS* 1,800 1,615 DEX-LEKPHARM DEXIREN 115 STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 2018 2019 2020 VA L U E - U S D 9,629 9,059 1,672 2018 2019 2020 Source: AMS MAT Q4 * Absolute pack  20 Dexketoprofen Brands In Iraq STRICTLY CONFIDENTIAL FOR INTERNAL USE ONLY 6 ampoules 5 ampoules Ilko- Turkey Lekpharm- Belarus Launched: Q2 2018 Launched: Q1 2020 Average pack price: 5.61 USD Average pack price: 14.54 USD (not selling anymore) Source: AMS MAT Q4 SITUATION ANALYSIS: Planning Context KETESSE SWOT Analysis < ----------------------------------------------- INTERNAL ----------------------------------